Mallinckrodt Sells Immunotherapy Business to CVC Capital for $925 Million

Deal Details::
Mallinckrodt has agreed to sell its immunotherapy business, Therakos, to CVC Capital Partners for $925 million.

Business Impact::
This sale marks a significant transaction in the immunotherapy sector, reflecting the growing interest in advanced therapeutic technologies.

Therakos Business::
Therakos is known for its photopheresis business, which involves the use of light to treat certain medical conditions.

CVC Capital::
The acquisition by CVC Capital Partners underscores the firm's commitment to investing in innovative healthcare technologies.

Market Context::
The deal highlights the ongoing consolidation and investment in the immunotherapy market, driven by the potential for groundbreaking treatments.